Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia research"
DOI: 10.1016/j.leukres.2017.12.012
Abstract: The National Comprehensive Cancer Network (NCCN) defines the following types of acute myeloid leukemia (AML) as favorable-risk: acute promyelocytic leukemia with t(15;17) (APL); AML with core-binding factor (CBF) rearrangements, including t(8;21) and inv(16) or t(16;16)… read more here.
Keywords: genotypic; risk; favorable risk; acute myeloid ... See more keywords
Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129166
Abstract: Background: Patients with favorable risk acute myeloid leukemia (AML) by European LeukemiaNet (ELN) criteria are treated with intensive chemotherapy that yields high remission rates and is often curative. Intensive chemotherapy typically includes cytarabine and anthracycline… read more here.
Keywords: cohort cohort; favorable risk; cohort; dose daunorubicin ... See more keywords
Prognostic Impact of CSF3R Mutations in Favorable Risk Childhood Acute Myeloid Leukemia.
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2019004179
Abstract: Truncation mutations in the granulocyte colony-stimulating factor receptor gene (CSF3R) are a rare abnormality in pediatric acute myeloid leukemia, and are usually associated either with mutations in CEBPA or with t(8;21). Through sequencing of over… read more here.
Keywords: myeloid leukemia; favorable risk; csf3r; acute myeloid ... See more keywords
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
Sign Up to like & getrecommendations! Published in 2021 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005240
Abstract: Key Points Safety and efficacy data demonstrated that atezolizumab alone or with azacitidine did not support a favorable risk-benefit profile in MDS. The differential toxicity profile observed between patients with R/R and those with HMA-naïve… read more here.
Keywords: benefit profile; favorable risk; atezolizumab alone; risk benefit ... See more keywords
Biomarker study of early death in patients with intermediate and favorable risk metastatic renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.530
Abstract: 530Background: The primary objective of this study was to determine whether severe systemic inflammation (SSI) could serve as a biomarker for terminal disease progression and early death in patients with intermediate and favorable risk metastatic… read more here.
Keywords: intermediate favorable; death; death patients; favorable risk ... See more keywords
Race as a prognostic factor in high-risk prostate cancer: An NCDB analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e16611
Abstract: e16611 Background: It is commonly held that race serves as a significant prognosticator in prostate cancer. However, it is unclear if race affects all risk groups similarly. We sought to analyze whether race, either African… read more here.
Keywords: prostate cancer; favorable risk; race; risk ... See more keywords
Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2018.188433
Abstract: Acute myeloid leukemia (AML) is a dynamic disease caused by accumulating, somatically acquired driver mutations generating branching competing clones.[1][1] In favorable-risk AML, high resolution genomic profiling by single nucleotide polymorphism array analysis of paired diagnostic-relapse… read more here.
Keywords: favorable risk; myeloid leukemia; acute myeloid;